CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.

NYSE: GSK share price and Q4 earnings results preview

What to expect and how to trade GSK’s upcoming results

GSK logo Source: Bloomberg

When are GSK results expected?

GSK is set to release its fourth quarter (Q4) 2022 results on 01 February 2023. The results are for the fiscal quarter ending December 2022.

What is ‘The Street’s’ expectation for the Q4 2022 results?

According to Refinitiv Eikon expectations for the upcoming results are as follows:

Revenue of $10,010 billion : -78.66% year on year (YoY)
Earnings per share (EPS): $0.50 (-58.14% YoY)

Analysts expects lower revenue and Earnings Per Share (EPS) for the fourth quarter of 2022 compared to a year ago but over the past year, results consistently came in better-than-expected.

Will this be the case this time round as well?

It will depend on whether the pharmaceutical and biotechnology behemoth GSK, formerly GlaxoSmithKline, having spun off its Haleon consumer products arm last summer, may perhaps consider offloading more of its residual stake in Haleon and on how it does in the race for a new respiratory syncytial virus (RSV) vaccination.

The virus, which together with the flu and Covid-19, has kept hospital admissions at record levels over the winter months, accounts for around half a million patients - mostly the very young and the elderly - being admitted to UK hospitals every year.

According to The Times “so serious are the health implications that governments across the world have been encouraging pharmaceutical companies to come up with a vaccine, with the prospect of billions of dollars of orders for the teams creating the best drug.”

The British newspaper estimates the RSV market to be worth $4 billion by 2027, making it a major prize for drug giants, “but, having failed to produce a Covid vaccine, the need to succeed is most acute for GSK and its chief executive, Dame Emma Walmsley.”

The Times also states that Britain’s GSK “is leading the way alongside Pfizer, with both having completed trials and submitted vaccines to the US Food & Drug Administration for approval late last year.”

Both GSK and Pfizer are expected to have their medicines approved in June but GSK’s vaccination rate seems to have a higher success rate in trials, at 83 per cent compared with Pfizer’s 67 per cent. Nonetheless, there remains a risk that Pfizer may offer its vaccine at a lower price in order to increase its market share, hurting GSK’s profit prospects.

How to trade GSK into the results

Refinitiv data shows a consensus analyst rating of ‘hold’ for GSK – 1 strong buy, 3 hold and 1 sell - with the median of estimates suggesting a long-term price target of $38.60 for the share, around 9% above where it is currently trading (as of 30/01/2023).

GSK analysts Source: Refinitiv
GSK analysts Source: Refinitiv

IG sentiment data shows that 97% of clients with open positions on the share (as of 30 January 2023) expect the price to rise over the near term, while 3% of clients expect the price to fall.

57% of clients who trade the share bought it this month and 50% this week.

GSK IG Source: IG
GSK IG Source: IG

GSK technical view

Since its early December spike to $39.74, the GSK share price on the New York Stock Exchange (NYSE) dropped towards the $35.00 mark, around which it has been oscillating in a +/- 70 cents band since mid-December.

Fourth-quarter earnings may surprise to the upside once more, having over the last four quarters consistently beaten consensus EPS estimates, in which case a break out of the recent sideways trading band may ensue.

Daily GSK chart Source: Tradingview
Daily GSK chart Source: Tradingview

For the bulls to be back in control, a rise and daily chart close above the 21 December to January highs at $35.73 to $35.85 would need to be seen, in which case the September-to-January uptrend may continue with the $39.74 December peak and the minor psychological $40.00 mark being back in the frame.

The September-to-January support line at $34.73 may offer short-term support.

Were earnings to disappoint, however, and a slide through the current January low at $34.23 and the early November high at $34.10 to be seen, the 61.8% Fibonacci retracement of the September-to-January advance at $32.77 could be revisited, and perhaps also the November trough at $31.22.

Monthly GSK chart Source: Tradingview
Monthly GSK chart Source: Tradingview

From a technical perspective the share price will remain long-term bearish while it trades below the April 2022 high at $46.97 on a daily chart closing basis.

This information has been prepared by IG, a trading name of IG Markets Ltd and IG Markets South Africa Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. See full non-independent research disclaimer and quarterly summary.

Seize a share opportunity today

Go long or short on thousands of international stocks.

  • Increase your market exposure with leverage
  • Get spreads from just 0.1% on major global shares
  • Trade CFDs straight into order books with direct market access

Live prices on most popular markets

  • Forex
  • Shares
  • Indices

Prices above are subject to our website terms and agreements. Prices are indicative only

Plan your trading week

Get the week’s market-moving news sent directly to your inbox every Monday. The Week Ahead gives you a full calendar of upcoming economic events, as well as commentary from our expert analysts on the key markets to watch.

You might be interested in…

Find out what charges your trades could incur with our transparent fee structure.

Discover why so many clients choose us, and what makes us a world-leading provider of CFDs.

Stay on top of upcoming market-moving events with our customisable economic calendar.